Kristian Vinter Juul, MD
Clinical R&D, Medical Science Urology, Ferring Pharmaceuticals A/S
Denmark
Dr. Kristian Vinter Juul is Medical Science Director at Ferring Pharmaceuticals. Over the last 14 years, Dr. Juul has worked in scientific and management positions in biotech and pharmaceutical industry. He has led the advancement of several New Chemical Entities into phase I-III and contributed with original scientific work published in peer reviewed journals and books covering a wide range of drugs and therapeutic areas.
Starting in 2001, and since 2010 being his main scientific speciality, his focus is antidiuresis therapy, including mechanism of action and clinical implications, within three major therapeutic areas: diabetes insipidus, nocturnal enuresis and nocturia – and any other abnormalities in which antidiuretic therapy may be of benefit. His main contribution to the field of science was the 2011 publication of significant gender differences in renal sentitivity to Desmopressin, a discovery with a number of clinical implications for future antidiuretic treatment
Antidiuresis, diabetes insipidus, nocturnal enuresis, nocturia, nocturnal polyuria, circadian control of urine production.
